A Long-term Follow-up Study in Patients Who Received BEAM-101

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Beam Therapeutics Inc.
Study ID
NCT07373639
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
14 Years - 37 Years
Healthy Volunteers
Not accepted

Interventions

  • Long-Term Follow-up Study of patients who received BEAM-101 — DRUG
    This is a Long-Term Follow-up Study of patients who received a single dose of BEAM-101 administered by IV following myeloablative conditioning with busulfan

Study Details

This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed for 13 years (a total of 15 years after receiving BEAM-101).

Key Dates

Start date
Dec 15, 2025
Status verified
Nov 2025
Primary completion
Feb 12, 2043
Completion
Feb 12, 2043

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: BTX-101-002 Long-term Follow-up on Patients who received BEAM-101
    All participants who received BEAM-101 in the BTX-AUT-001 trial will be asked to participate in this long-term follow-up study

Primary Outcome Measure

Long-Term Safety Monitoring and Mortality Assessment [ Time Frame: Up to 13 years ]

Central Contacts

Locations (17)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35233
Medical Information
[email protected]
8573278641
Phoenix Children's HospitalPhoenixArizona85016
Medical Information
[email protected]
8573278641
Mayo Clinic FloridaJacksonvilleFlorida32224
Medical Information
[email protected]
8573278641
Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- EglestonAtlantaGeorgia30329
Medical Information
[email protected]
8573278641
Boston Children's HospitalBostonMassachusetts02215
Medical Information
[email protected]
8573278641
Henry Ford Cancer CenterDetroitMichigan48202
Medical Information
[email protected]
8573278641
University of MinnesotaMinneapolisMinnesota55455
Medical Information
[email protected]
8573278641
Washington University School of Medicine in St. LouisSt LouisMissouri63110
Medical Information
[email protected]
8573278641
Hackensack University Medical CenterHackensackNew Jersey07601
Medical Information
[email protected]
8573278641
Columbia University Irving Medical CenterNew YorkNew York10032
Medical Information
[email protected]
8573278641
The Clevland Clinic FoundationClevelandOhio44195
Medical Information
[email protected]
8573278641
University Hospitals Clevland Medical CenterClevelandOhio44106
Medical Information
[email protected]
8573278641
Children's Hospital of PhiladelphiaPhiladelphiaPennsylvania19104
Medical Information
[email protected]
8573278641
Medical University of South CarolinaCharlestonSouth Carolina29425
Medical Information
[email protected]
8573278641
St. Jude Children's Research HospitalMemphisTennessee38105
Medical Information
[email protected]
8573278641
The Children's Hospital at TriStar CentennialNashvilleTennessee37203
Medical Information
[email protected]
8573278641
Medical College of WisconsinMilwaukeeWisconsin53226
Medical Information
[email protected]
8573278641

Find similar trials in Birmingham, AL

By condition
Sickle cell disease
By research site
University of Alabama at Birmingham· Birmingham, ALPhoenix Children's Hospital· Phoenix, AZMayo Clinic Florida· Jacksonville, FLChildren's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston· Atlanta, GABoston Children's Hospital· Boston, MAHenry Ford Cancer Center· Detroit, MI

Related Studies